drugset / Trial / NCT02222922
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Non-randomizedOpen-labelTreatment
Summary
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Timeline
- Start
- 2014-10-17
- Primary completion
- 2019-11-05
- Completion
- 2019-11-05
Publications
- Johnson M, El-Khoueiry A, Hafez N, Lakhani N, Mamdani H, Rodon J, Sanborn RE, Garcia-Corbacho J, Boni V, Stroh M, Hannah AL, Wang S, Castro H, Spira A. Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2021 Aug 15;27(16):4521-4530. doi: 10.1158/1078-0432.CCR-21-0194. Epub 2021 Jun 3.
- Maitland ML, Sachdev JC, Sharma MR, Moreno V, Boni V, Kummar S, Stringer-Reasor E, Lakhani N, Moreau AR, Xuan D, Li R, Powell EL, Jackson-Fisher A, Bowers M, Alekar S, Xin X, Tolcher AW, Calvo E. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clin Cancer Res. 2021 Aug 15;27(16):4511-4520. doi: 10.1158/1078-0432.CCR-20-3757. Epub 2021 Jun 3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Cofetuzumab Pelidotin | Other / unclassified | 0.2 mg/kg | Intravenous |
| Subject | Cofetuzumab Pelidotin | Other / unclassified | 2.1 mg/kg | Intravenous |
| Subject | Cofetuzumab Pelidotin | Other / unclassified | 2.8 mg/kg | Intravenous |
| Subject | Cofetuzumab Pelidotin | Other / unclassified | 3.2 mg/kg | Intravenous |
| Subject | Cofetuzumab Pelidotin | Other / unclassified | 3.7 mg/kg | Intravenous |
| Subject | Fluconazole | Small molecule | — | — |